Intas Pharmaceuticals to acquire Udenyca from Coherus for $558m.

Intas Pharmaceuticals, an Indian multinational pharmaceutical company, agreed to acquire Udenyca, a pharmaceutical compan, from Coherus, a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies, for $558m. “The proposed divestiture of UDENYCA represents the successful execution of our strategy to focus R&D and commercial resources on Coherus’ innovative immuno-oncology portfolio and to strengthen our financial position," Denny Lanfear, Coherus Chairman and CEO.